Categories: Health&Beauty

Gilead Subsidiary to Launch Authorized Generics of Epclusaand Harvoni for the Treatment of Chronic Hepatitis C

The FINANCIAL — Gilead Sciences, Inc. announced plans to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.

The authorized generics will launch at a list price of $24,000 for the most common course of therapy and will be available in January 2019.

Since the launch of Gilead’s first HCV medication in 2013, the average price paid for each bottle of medicine in the United States has decreased by more than 60 percent off of the public list prices, across health insurers and government payers. Due to the complexity and structure of the U.S. healthcare system, however, these discounts provided by Gilead may not always translate into lower costs for patients.

ADVERTISEMENT

Further, existing contracts, together with laws associated with government pricing policies, make it challenging to quickly lower a product’s list price once it is on the market.

The authorized generics are priced to more closely reflect the discounts that health insurers and government payers receive today. Insurers will have the choice of offering either the authorized generics or the branded medications for both Epclusa and Harvoni. In the Medicare Part D setting, the authorized generics could save patients up to $2,500 in out-of-pocket costs per course of therapy.

The authorized generics will also offer substantial savings to state managed Medicaid plans that do not currently benefit from negotiated rebates and that represent a significant number of people in need, potentially opening up access to our medications to beneficiaries who were previously denied coverage.

 

The FINANCIAL

Recent Posts

Bank of America Study Finds 84% of Employers Now Say Offering Financial Wellness Tools Helps Increase Employee Retention

The FINANCIAL -- 97% of employers feel responsible for employee financial wellness, with 91% seeing…

22 hours ago

How Global South cities can work better: free course based on Oxford-led urban research

A new, free course ‘Shaping Urban Futures’, aimed at planners, policymakers and people with an…

22 hours ago

Discovery of new nanowire assembly process could enable more powerful computer chips

Researchers from Oxford University’s Department of Materials have developed a technique to precisely manipulate and…

22 hours ago

Face to face with ancient Egyptians

Realistic mummy portraits shed light on life, death in multicultural Roman era 2,000 years ago. Realistic…

22 hours ago

What makes us human? It’s all in the hips

New study shows how pelvis evolved for walking upright, allowing birth of offspring with larger…

23 hours ago

Genetic tests set to reduce burden of joint replacement surgery

A range of ground-breaking genetic tests could help predict whether joint replacements succeed or fail. These…

23 hours ago